

Roxanne Hastie

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4474794/roxanne-hastie-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51 papers	853 citations	16 h-index	28 g-index
59 ext. papers	1,126 ext. citations	4.1 avg, IF	4.14 L-index

#	Paper	IF	Citations
51	PSG7 and 9 (Pregnancy-Specific β Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia.. <i>Journal of the American Heart Association</i> , 2022 , e024536	6	1
50	Time to resolution of tubal ectopic pregnancy following methotrexate treatment: A retrospective cohort study. <i>PLoS ONE</i> , 2022 , 17, e0268741	3.7	1
49	Aspirin to prevent pre-eclampsia. <i>Drug and Therapeutics Bulletin</i> , 2021 , 59, 56-59	0.9	0
48	PROVE-Pre-Eclampsia Obstetric Adverse Events: Establishment of a Biobank and Database for Pre-Eclampsia. <i>Cells</i> , 2021 , 10,	7.9	3
47	Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues. <i>Placenta</i> , 2021 , 109, 28-31	3.4	1
46	Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 95.e1-95.e12	6.4	16
45	Management of late preterm preeclampsia: a comparison of maternal and fetal indications for delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 1-10	2	
44	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. <i>Journal of the American Heart Association</i> , 2021 , 10, e020302	6	4
43	Severe maternal morbidity in the Asia Pacific: a systematic review and meta-analysis. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 14, 100217	5	0
42	Growth trajectory of preterm small-for-gestational-age neonates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 1-7	2	1
41	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. <i>Placenta</i> , 2021 , 114, 22-28	3.4	0
40	Preventable stillbirths in the Solomon Islands - A hidden tragedy. <i>The Lancet Regional Health - Western Pacific</i> , 2020 , 5, 100050	5	0
39	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. <i>Nature Communications</i> , 2020 , 11, 2411	17.4	18
38	Duration of labor among women with hypertensive disorders of pregnancy; A Swedish register cohort study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020 , 251, 114-118	2.4	0
37	Accuracy of clinical suspicion of growth restriction at term despite a normal growth ultrasound: A retrospective cohort study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020 , 60, 568-573	1.7	
36	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. <i>Placenta</i> , 2020 , 95, 78-83	3.4	7
35	Acupuncture in pregnancy; primum non nocere. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020 , 127, 87	3.7	1

34	Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020 , 46, 531-535	1.9	0
33	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2020 ,	6.4	19
32	Maternal mortality at the National Referral Hospital in Honiara, Solomon Islands over a five-year period. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020 , 60, 183-187	1.7	3
31	Screening circulating proteins to identify biomarkers of fetal macrosomia. <i>BMC Research Notes</i> , 2019 , 12, 587	2.3	
30	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. <i>Placenta</i> , 2019 , 87, 53-57	3.4	4
29	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. <i>Scientific Reports</i> , 2019 , 9, 235	4.9	4
28	Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women. <i>Hypertension</i> , 2019 , 73, 1097-1103	8.5	15
27	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. <i>EBioMedicine</i> , 2019 , 41, 636-648	8.8	22
26	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. <i>Pregnancy Hypertension</i> , 2019 , 16, 16-25	2.6	6
25	Prediction of adverse maternal outcomes in preeclampsia at term. <i>Pregnancy Hypertension</i> , 2019 , 18, 75-81	2.6	5
24	Systematic review of areca (betel nut) use and adverse pregnancy outcomes. <i>International Journal of Gynecology and Obstetrics</i> , 2019 , 147, 292-300	4	4
23	The incidence of hypertensive disorders of pregnancy following sperm donation in IVF: an Australian state-wide retrospective cohort study. <i>Human Reproduction</i> , 2019 , 34, 2541-2548	5.7	4
22	Predictive Value of the Signs and Symptoms Preceding Eclampsia: A Systematic Review. <i>Obstetrics and Gynecology</i> , 2019 , 134, 677-684	4.9	9
21	EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion. <i>Hypertension</i> , 2019 , 73, 659-670	8.5	27
20	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. <i>EBioMedicine</i> , 2018 , 29, 166-176	8.8	3
19	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. <i>PLoS ONE</i> , 2018 , 13, e0188845	3.7	25
18	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. <i>Pregnancy Hypertension</i> , 2018 , 14, 125-130	2.6	0
17	Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. <i>Hypertension</i> , 2017 , 69, 457-468	8.5	84

16	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. <i>Reproductive Sciences</i> , 2017 , 24, 1245-1252	3	11
15	Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. <i>Hypertension</i> , 2017 , 70, 1014-1024	8.5	16
14	Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. <i>BMC Pregnancy and Childbirth</i> , 2016 , 16, 117	3.2	32
13	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. <i>Pregnancy Hypertension</i> , 2016 , 6, 95-102	2.6	6
12	Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks of gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 521.e1-521.e8	6.4	17
11	Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 356.e1-356.e15	6.4	121
10	Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. <i>Placenta</i> , 2015 , 36, 932-7	3.4	8
9	Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. <i>Hypertension</i> , 2015 , 66, 687-97; discussion 445	8.5	111
8	Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. <i>Hypertension</i> , 2015 , 66, 1251-9	8.5	58
7	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. <i>Hypertension</i> , 2015 , 66, 1073-81	8.5	24
6	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. <i>Molecular and Cellular Endocrinology</i> , 2015 , 413, 202-8	4.4	23
5	Placental SEMA3B expression is not altered in severe early onset preeclampsia. <i>Placenta</i> , 2014 , 35, 1102-5	3.4	5
4	Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. <i>Placenta</i> , 2014 , 35, 1106-9	3.4	16
3	The effect of pre-existing maternal obesity and diabetes on placental mitochondrial content and electron transport chain activity. <i>Placenta</i> , 2014 , 35, 673-83	3.4	72
2	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. <i>Pregnancy Hypertension</i> , 2014 , 4, 255-8	2.6	
1	Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. <i>Pregnancy Hypertension</i> , 2014 , 4, 287-95	2.6	45